These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 8927112)

  • 1. Tumor necrosis factor receptor: Fc fusion protein in septic shock.
    Glauser MP; Cohen J
    N Engl J Med; 1996 Nov; 335(21):1608; author reply 1608-9. PubMed ID: 8927112
    [No Abstract]   [Full Text] [Related]  

  • 2. Tumor necrosis factor receptor: Fc fusion protein in septic shock.
    Whiteley MS
    N Engl J Med; 1996 Nov; 335(21):1607-8; author reply 1608-9. PubMed ID: 8927111
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group.
    Fisher CJ; Agosti JM; Opal SM; Lowry SF; Balk RA; Sadoff JC; Abraham E; Schein RM; Benjamin E
    N Engl J Med; 1996 Jun; 334(26):1697-702. PubMed ID: 8637514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor necrosis factor receptor: Fc fusion protein does not improve septic shock and may increase mortality in human.
    Atallah AN
    Sao Paulo Med J; 1996; 114(3):1151. PubMed ID: 9181744
    [No Abstract]   [Full Text] [Related]  

  • 5. Administration of noncytolytic IL-10/Fc in murine models of lipopolysaccharide-induced septic shock and allogeneic islet transplantation.
    Zheng XX; Steele AW; Nickerson PW; Steurer W; Steiger J; Strom TB
    J Immunol; 1995 May; 154(10):5590-600. PubMed ID: 7730658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effect of recombinant human tumor necrosis factor receptor type II-Fc fusion protein antibody on cytokines and bone metabolism in patients with juvenile idiopathic arthritis].
    Li L; Zhang X; Cui Y; Lu YY; Wang SX; Dong GF; Shi YZ; Luo RQ; Lei YX
    Zhonghua Yi Xue Za Zhi; 2010 Aug; 90(31):2205-8. PubMed ID: 21029662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anticytokine therapy in rheumatoid arthritis.
    Firestein GS; Zvaifler NJ
    N Engl J Med; 1997 Jul; 337(3):195-7. PubMed ID: 9219708
    [No Abstract]   [Full Text] [Related]  

  • 8. Soluble TNFR II/IgG1 Fc fusion protein treatment in the LPS-mediated septic shock of rats.
    Guo Z; Wang S; Jiao Q; Xu M; Xu Z
    Biomed Pharmacother; 2009 Aug; 63(7):537-42. PubMed ID: 18848768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Minimal tumor necrosis factor receptor binding protein: optimum biological activity of a truncated p55 soluble tumor necrosis factor receptor-IgG fusion protein.
    Corcoran AE; Scallon BJ; Trinh H; Chernajovsky Y; Ghrayeb J; Feldmann M
    Eur Cytokine Netw; 1998 Sep; 9(3):255-62. PubMed ID: 9831174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Construction and preclinical characterization of Fc-mGITRL for the immunotherapy of cancer.
    Hu P; Arias RS; Sadun RE; Nien YC; Zhang N; Sabzevari H; Lutsiak ME; Khawli LA; Epstein AL
    Clin Cancer Res; 2008 Jan; 14(2):579-88. PubMed ID: 18223234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. USAN Council. List No.407. New names. Lenercept.
    Clin Pharmacol Ther; 1998 Aug; 64(2):234. PubMed ID: 9758530
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment of rheumatoid arthritis with a tumor necrosis factor receptor-Fc fusion protein.
    Mannik M; Wener M
    N Engl J Med; 1997 Nov; 337(21):1560; author reply 1560-1. PubMed ID: 9380131
    [No Abstract]   [Full Text] [Related]  

  • 13. Therapeutic efficacy of a soluble receptor activator of nuclear factor kappaB-IgG Fc fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy.
    Oyajobi BO; Anderson DM; Traianedes K; Williams PJ; Yoneda T; Mundy GR
    Cancer Res; 2001 Mar; 61(6):2572-8. PubMed ID: 11289133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cloning, expression and bio-activity assay of chimeric fusion protein sTNFRII-IgG Fc].
    Xu CX; Yao LH; Zu D; Chen AJ; Huang GJ; Zhang ZQ
    Sheng Wu Gong Cheng Xue Bao; 2002 Jan; 18(2):178-81. PubMed ID: 12148279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytokine modifiers: pipe dream or reality?
    Abraham E
    Chest; 1998 Mar; 113(3 Suppl):224S-227S. PubMed ID: 9515897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical evaluation and radiological observation of recombinant human tumor necrosis factor receptor-Fc fusion protein in treatment of active ankylosing spondylitis].
    Pan XY; Li J; Pang J; Dai SH; Chen WG
    Zhonghua Yi Xue Za Zhi; 2008 May; 88(20):1408-11. PubMed ID: 18953881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor necrosis factor receptor-IgG fusion protein for targeted drug delivery across the human blood-brain barrier.
    Hui EK; Boado RJ; Pardridge WM
    Mol Pharm; 2009; 6(5):1536-43. PubMed ID: 19624167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cloning and expression of human TNFR (P55)-IgG Fc fusion protein in eukaryotic cells].
    An N; Xu C; Zhang Z
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2001 Jun; 15(2):116-7. PubMed ID: 11436637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of RANK blockade and osteoclast depletion in a model of pure osteoblastic prostate cancer metastasis in bone.
    Whang PG; Schwarz EM; Gamradt SC; Dougall WC; Lieberman JR
    J Orthop Res; 2005 Nov; 23(6):1475-83. PubMed ID: 16005175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Next-generation Fc chimeric proteins: avoiding immune-system interactions.
    Junghans RP
    Trends Biotechnol; 1997 May; 15(5):155. PubMed ID: 9161048
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.